605
Participants
Start Date
September 9, 2024
Primary Completion Date
December 9, 2024
Study Completion Date
June 4, 2025
Flucelvax (ccIIV4)
Participants will receive Flucelvax (ccIIV4)
Flublok (RIV) or Fluzone (IIV)
Participants will receive Flublok (RIV) or Fluzone (IIV)
Department of Family Medicine, University of Pittsburgh School of Medicine, Pittsburgh
Centers for Disease Control and Prevention, Atlanta
University Hospitals Cleveland Medical Center, Cleveland
VA Northeast Ohio Healthcare System (VANEOHS), Cleveland
Washington University IDCRU, St Louis
Valleywise Health Comprehensive Health Center, Phoenix
ASU Biodesign Institute, Tempe
Lead Sponsor
Centers for Disease Control and Prevention
FED
Arizona State University
OTHER
University Hospitals Cleveland Medical Center
OTHER
University of Pittsburgh
OTHER
Washington University School of Medicine
OTHER
VA Medical Center-Cleveland
UNKNOWN
Duke University
OTHER